|
WO2017136355A1
|
|
Aglycosylated anti-bb antibodies and uses thereof
|
|
WO2017136350A1
|
|
AGLYCOSYLATED ANTI-C3b ANTIBODIES AND USES THEREOF
|
|
US2016333080A1
|
|
AGLYCOSYLATED ANTI-Bb ANTIBODIES AND USES THEREOF
|
|
US2016333079A1
|
|
AGLYCOSYLATED ANTI-C3b ANTIBODIES AND USES THEREOF
|
|
WO2016109822A1
|
|
Formulation of aglycosylated therapeutic antibodies
|
|
US2016002348A1
|
|
Anti-factor Bb antibodies
|
|
CA2934462A1
|
|
Compositions and methods of treating ocular diseases
|
|
US2014206644A1
|
|
Methods and compositions for inhibiting cellular proliferation and surgical adhesion
|
|
US2014186348A1
|
|
Humanized and chimeric anti-properdin antibodies
|
|
CN104870474A
|
|
Alternative pathway specific antibodies for treating hemolytic diseases
|
|
CN104220454A
|
|
Humanized and chimeric anti-factor Bb antibodies and uses thereof
|
|
AU2013243574A1
|
|
Humanized and chimeric anti-factor C3 antibodies and uses thereof
|
|
US2014127204A1
|
|
Anti-properdin antibodies
|
|
AU2012362217A1
|
|
Aglycosylated human antibody and fusion protein and uses thereof
|
|
EP2646821A2
|
|
Neoantibodies for diagnosing tissue injury
|
|
AU2011224224A1
|
|
Humanized and chimeric anti-properdin antibodies
|
|
EP2544694A2
|
|
A method for inhibiting alternative pathway mediated disorders with anti-properdin antibodies that inhibit c5 interactions with properdin
|
|
WO2010057084A1
|
|
Method of treating ischemia reperfusion injury
|
|
WO2009029669A1
|
|
Method of inhibiting complement activation with factor bb specific antibodies
|
|
WO2009026584A1
|
|
Methods of treating inflammatory conditions with adrenergic antagonists
|
